Sophia Genetics initiated with a Buy at BTIG

BTIG analyst Mark Massaro initiated coverage of Sophia Genetics with a Buy rating and $6.00 price target. The analyst states that he is impressed by the company’s strong financial profile given its above 90% recurring revenue and targeting 30%-35% topline CAGR with above 70% in gross margins by 2025. Most of Sophia Genetics’ revenue is in Europe today, but the company should make further inroads into the U.S. market, Massaro tells investors in a research note, stating that he sees "significant upside potential" for this stock which he believes to be "disconnected from its fundamentals".